NCT05972200 V5/MT Stimulation on Reading and Reading-related Measures in Developmental Dyslexia
| NCT ID | NCT05972200 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bambino Gesù Hospital and Research Institute |
| Condition | Developmental Dyslexia |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 36 participants in total. It began in 2023-09-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The present study grounds on the absence of evidence-based treatment in individuals with developmental dyslexia (DD). At this topic, the present study will explore the potential effect of transcranial direct current stimulation (tDCS) over left hemispheric direct Lateral Geniculate Nucleus (LGN)-V5/MT pathway, cerebral areas usually disrupted in individuals with DD. The investigators hypothesized that active tDCS over V5/MT will boost reading skills in children and adolescents with DD. On the contrary, sham (placebo condition) tDCS over V5/MT or active (control condition) tDCS over V1 will not have significant effect in improving reading skills. Further, both active and sham tDCS will be safe and well tolerated.
Eligibility Criteria
Inclusion Criteria: * Italian speakers right-handed children and adolescents with dyslexia (DSM-5, APA 2013); * Word/nonword/text reading accuracy and/or speed at least 2 Standard Deviations below the mean for school-age; * nv IQ ≥ 85; * normal hearing and normal or corrected-to-normal vision. Exclusion Criteria: * Having a comorbidity with other primary psychiatric/neurological diagnosis (e.g., depression, anxiety, autism, ADHD); * Having a personal history of neurological/medical/genetic diseases; * Having ongoing drug treatment influencing brain function; * Having epilepsy o family history of epilepsy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05972200 clinical trial?
This trial is open to participants of all sexes, aged 8 Years or older, up to 13 Years, studying Developmental Dyslexia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05972200 currently recruiting?
Yes, NCT05972200 is actively recruiting participants. Contact the research team at deny.menghini@opbg.net for enrollment information.
Where is the NCT05972200 trial being conducted?
This trial is being conducted at Roma, Italy.
Who is sponsoring the NCT05972200 clinical trial?
NCT05972200 is sponsored by Bambino Gesù Hospital and Research Institute. The trial plans to enroll 36 participants.